Immunic: Datos principales de la fase 3 ENSURE para vidofludimus calcium en RMS esperados para finales de 2026

La compañía anunció que los datos principales de los ensayos gemelos de fase 3 ENSURE-1 y ENSURE-2 de vidofludimus calcium en esclerosis múltiple recurrente se esperan para finales de 2026. Esta lectura es el próximo catalizador regulatorio importante e informará la presentación planificada de la NDA a mediados de 2027.

Datos clave

Presentado: 26 feb 2026, 12:00
Evento: Resultados principales
Dirección: Neutral
Empresa: IMUXImmunic
Activo: vidofludimus calcium
Fuente: SEC 8-K
Confianza: Con fuente

Extracto de la fuente

EX-99.1 2 e665186_ex99-1.htm Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update – Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 – – Raised Proceeds of $200 Million in a Private Placement, with Potential for up to an Additional $200 Million – – Net Proceeds Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis and Begin of Transition into a Commercial Organization – NEW YORK, February 26, 2026 – Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financ

SEC 8-K